10X Genomics, a Bay Area startup that’s building out extensive next-generation sequencing services, just closed out a $55 million Series C round – meant largely to fuel sales and marketing growth.
Investors include Fidelity Management, Softback, JS Capital Management, Venrock, Foresite Capital, and Paladin Capital.
Beyond Analytics: How Sellers Dorsey is Hard-Coding Value into Medicaid Policy [Video]
How to turn analytics into actual policy outcomes.
The company’s product suite uses whole genome sequencing, single gene expression analysis and careful exome analysis to unveil new structural variants and haplotypes – thus painting a broader picture of human health. It sells instruments, reagents and software to make sense of a huge swath of sequenced genetic data.
Notably, last month 10X Genomics signed a comarketing agreement with Illumina to promote its Linked-Read sequencing products.